Exploring how gut bacteria affect weight regain after losing weight
Official title: The Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment
Run by Weizmann Institute of Science · NCT06681246 · Data updated 2026-11-12
This study tests whether taking antibiotics after losing weight can help people keep the weight off by looking at how gut bacteria play a role in weight maintenance.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Weizmann Institute of Science Academic / other |
| Locations | 1 site (Rehovot) |
| Status | Recruiting |
| Started | December 11, 2024 |
| Main results expected | December 2026 |
| Study ends | December 2027 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT06681246 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-65 with a BMI between 28 and 35 who are capable of using a smartphone application.
✕Probably not a fit
Patients with chronic diseases, recent cancer treatment, or significant psychiatric disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study investigates the impact of antibiotic treatment on preventing weight regain in individuals who have successfully lost weight. Participants will undergo a personalized hypocaloric diet followed by a 10-day course of either antibiotics or a placebo. The study includes microbiota profiling and metabolomics assessments to understand the relationship between gut bacteria and weight maintenance. Participants will be monitored for a total of one year, with follow-up meetings to assess outcomes.
Why it matters
Potential benefit: If successful, this study could provide a novel approach to help individuals maintain weight loss and reduce the risk of obesity-related health complications.
How similar studies have gone: While the role of the microbiome in obesity is being explored, this specific approach using antibiotics for weight maintenance is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 28 \< BMI\< 40 * Age - 18-65 * Capable of working with a smartphone application Exclusion Criteria: * Consumption of antibiotics/probiotics/oral antifungals 2 months prior to the first day of the experiment. * Pregnancy, fertility treatments, breastfeeding women six months prior to enrollment and during the study. * Chronic disease, to the discretion of the study team (e.g. AIDS, Cushing syndrome, CKD, acromegaly etc.) * Cancer and recent anticancer treatment * Psychiatric disorders, to the discretion of the study team. * Coagulation disorders * IBD (inflammatory bowel diseases) * Bariatric surgery. * Eating disorders (Anorexia nervosa. Bulimia nervosa. Binge eating disorder, Night eating syndrome). * Alcohol or substance abuse * Weight loss attempts 6 months prior to the first day of the experiment - using weight loss medication. * Drastic changes in nutritional habits six months prior to the first day of the study - to the discretion of the study team. * Allergy to penicillin. * Life threatening reaction after consumption of cephalosporins. * History of CDI * Liver disease * History of serious unresolved diarrhea in response to antibiotic treatment to the discretion of the study doctor.
Where it's running
-
Weizmann Institute of Science
Rehovot, Israel Recruiting
Study contacts
- Principal investigator: Hila Elinav, Doctor — Hadassah Medical Organization
- Study coordinator: Eran Elinav, Professor
- Email: Eran.Elinav@weizmann.ac.il
- Phone: +97289349174
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fasted versus fed aerobic exercise for weight loss and heart health
This 16-week program will see if doing aerobic exercise before breakfast (fasted) versus after eating helps adults with overweight or obesity lose more weight and improve heart-related measures.
-
Personalized weight-loss medication plan for adults with bipolar disorder
This pilot tests whether matching FDA-approved weight-loss medicines to specific obesity types helps adults aged 18–65 with bipolar disorder lose weight.
-
Efsubaglutide alfa for weight loss after metabolic surgery
This trial will test whether efsubaglutide alfa helps people who remain obese six months after metabolic surgery lose weight and improve obesity-related health problems.
-
Family COMIDA — helping Hispanic families choose healthier foods to prevent and reduce obesity
This program tests family-centered support (parent counseling, weekly phone coaching, monthly group sessions, and child education) to help Hispanic parents/caregivers and their 8–12-year-old children prevent or reduce obesity.
-
Protein supplements with semaglutide and a calorie-restricted diet for weight loss
This will test whether adding daily protein supplements to semaglutide plus a calorie-restricted diet helps adults with overweight or obesity lose more weight, preserve muscle, and reduce weight regain.
-
Probiotic or semaglutide plus diet to reduce body weight
This project will test whether adding a probiotic (Lactobacillus paracasei LC-19) or semaglutide to a calorie-restricted diet helps overweight adults lose weight and improve blood sugar and lipid levels.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.